Proposed oncogenic mechanisms to achieve increased SOX9 include transcriptional activation by ERG [10], which is highly expressed in tumours with TMPRSS2:ERG fusions, and loss of Zbtb7a, encoding a protein that antagonizes SOX9 activity [11]. Here, ZBTB7A is linked to neoplasm.